News

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market Company Intends to Request Hearing to Appeal in a Timely Manner MIRAMAR, Fla., Dec. 23, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported on December 17, 2024, the Company received written notice from the Listing Qualifications Staff (“Staff”) that it had failed to re-gain compliance for continued listing requirements of the Nasdaq Global Markets.

12/23/2024

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 6,717,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced above market under Nasdaq rules.

11/18/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is HCW Biologics Inc. (HCWB) a buy, sell, or hold?

HCW Biologics Inc. (HCWB) can sell. Click on Rating Page for detail.

What is HCW Biologics Inc.'s stock price?

The price of HCW Biologics Inc. (HCWB) is 0.342 and it was updated on 2025-01-14 13:00:52.

Is HCW Biologics Inc. (HCWB) overvalued or undervalued?

Currently HCW Biologics Inc. (HCWB) is in undervalued.

News

From:

To:

News
Why Is Penny Stock HCW Biologics Surging On Monday? HCW Biologics Inc HCWB stock is trading higher during Monday premarket with a strong session volume of 10.03 million versus an average volume of 48.02K, as per data from Benzinga Pro. Mon, Nov. 18, 2024
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical molecules HCW Biologics to receive upfront payment of $7 million and is eligible to receive additional milestone payments and double-digit royalties on future product sales MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd. Mon, Nov. 18, 2024
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2024. Thu, Nov. 14, 2024
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction This release has made a correction to a release issued under the same headline on August 14, 2024, by HCW Biologics, Inc. (NASDAQ: HCWB), to show the amount included in the condensed interim balance sheet for Cash and cash equivalents as of December 31, 2023 as $3,595,101, not $95,101 as previously stated. The full text of the corrected release is as follows: MIRAMAR, Fla. Fri, Aug. 23, 2024
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2024. Wed, Aug. 14, 2024

SEC Filings

SEC Filings
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 12/23/2024
HCW Biologics Inc. (HCWB) - D SEC Filings 12/05/2024
HCW Biologics Inc. (HCWB) - SC 13D/A SEC Filings 11/22/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 11/22/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 11/20/2024
HCW Biologics Inc. (HCWB) - 424B2 SEC Filings 11/20/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 11/18/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 11/14/2024
HCW Biologics Inc. (HCWB) - 10-Q - Quarterly Report SEC Filings 11/14/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 09/20/2024
HCW Biologics Inc. (HCWB) - 8-K/A - Current report SEC Filings 08/23/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 08/14/2024
HCW Biologics Inc. (HCWB) - 10-Q - Quarterly Report SEC Filings 08/14/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 08/12/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 07/18/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 06/20/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 06/17/2024
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/17/2024
HCW Biologics Inc. (HCWB) - ARS/A SEC Filings 05/20/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 05/15/2024
HCW Biologics Inc. (HCWB) - 10-Q - Quarterly Report SEC Filings 05/15/2024
HCW Biologics Inc. (HCWB) - 10-K/A - Current report SEC Filings 05/15/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 05/03/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 05/01/2024
HCW Biologics Inc. (HCWB) - DEFA14A SEC Filings 04/26/2024
HCW Biologics Inc. (HCWB) - DEF 14A SEC Filings 04/26/2024
HCW Biologics Inc. (HCWB) - ARS SEC Filings 04/26/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 04/01/2024
HCW Biologics Inc. (HCWB) - 10-K - Current report SEC Filings 04/01/2024
HCW Biologics Inc. (HCWB) - D SEC Filings 02/27/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 02/22/2024
HCW Biologics Inc. (HCWB) - 4 SEC Filings 02/22/2024
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 01/12/2024
HCW Biologics Inc. (HCWB) - 4 SEC Filings 12/11/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 11/20/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 10/23/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/18/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/15/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/13/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/12/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/08/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/07/2023
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 08/31/2023
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 08/24/2023
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 08/11/2023
HCW Biologics Inc. (HCWB) - 10-Q - Quarterly Report SEC Filings 08/11/2023
HCW Biologics Inc. (HCWB) - 10-Q/A - Quarterly Report SEC Filings 08/10/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/15/2023
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 06/14/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/09/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/08/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/07/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/02/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/01/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 05/31/2023
HCW Biologics Inc. (HCWB) - 4 SEC Filings 05/24/2023
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 05/09/2023
HCW Biologics Inc. (HCWB) - 10-Q - Quarterly Report SEC Filings 05/09/2023
HCW Biologics Inc. (HCWB) - DEFA14A SEC Filings 04/27/2023
HCW Biologics Inc. (HCWB) - DEF 14A SEC Filings 04/27/2023
HCW Biologics Inc. (HCWB) - ARS SEC Filings 04/27/2023
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 04/27/2023
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 03/28/2023
HCW Biologics Inc. (HCWB) - 10-K - Current report SEC Filings 03/28/2023
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 12/07/2022
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 11/07/2022
HCW Biologics Inc. (HCWB) - 10-Q - Quarterly Report SEC Filings 11/07/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 11/03/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/12/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/07/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/01/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 08/30/2022
HCW Biologics Inc. (HCWB) - EFFECT SEC Filings 08/29/2022
HCW Biologics Inc. (HCWB) - EFFECT SEC Filings 08/29/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 08/26/2022
HCW Biologics Inc. (HCWB) - CORRESP SEC Filings 08/25/2022
HCW Biologics Inc. (HCWB) - UPLOAD SEC Filings 08/24/2022
HCW Biologics Inc. (HCWB) - S-3 SEC Filings 08/19/2022
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 08/18/2022
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 08/17/2022
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 08/12/2022
HCW Biologics Inc. (HCWB) - 10-Q - Quarterly Report SEC Filings 08/12/2022
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 08/03/2022
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 06/17/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/17/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/15/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/13/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/10/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/09/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/08/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/06/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 06/02/2022
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 05/19/2022
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 05/13/2022
HCW Biologics Inc. (HCWB) - 10-Q - Quarterly Report SEC Filings 05/13/2022
HCW Biologics Inc. (HCWB) - DEF 14A SEC Filings 04/25/2022
HCW Biologics Inc. (HCWB) - 10-K - Current report SEC Filings 03/29/2022
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 03/28/2022
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 01/24/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 01/19/2022
HCW Biologics Inc. (HCWB) - 4 SEC Filings 12/07/2021
HCW Biologics Inc. (HCWB) - 4 SEC Filings 12/03/2021
HCW Biologics Inc. (HCWB) - 4 SEC Filings 11/26/2021
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 11/12/2021
HCW Biologics Inc. (HCWB) - 10-Q - Quarterly Report SEC Filings 11/12/2021
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 10/28/2021
HCW Biologics Inc. (HCWB) - 4/A SEC Filings 10/28/2021
HCW Biologics Inc. (HCWB) - 4 SEC Filings 10/28/2021
HCW Biologics Inc. (HCWB) - 3 SEC Filings 10/28/2021
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 10/27/2021
HCW Biologics Inc. (HCWB) - 4/A SEC Filings 10/07/2021
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/17/2021
HCW Biologics Inc. (HCWB) - 4/A SEC Filings 09/10/2021
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/10/2021
HCW Biologics Inc. (HCWB) - 4 SEC Filings 09/02/2021
HCW Biologics Inc. (HCWB) - 4 SEC Filings 08/30/2021
HCW Biologics Inc. (HCWB) - 4 SEC Filings 08/27/2021
HCW Biologics Inc. (HCWB) - 4/A SEC Filings 08/24/2021
HCW Biologics Inc. (HCWB) - 4 SEC Filings 08/24/2021
HCW Biologics Inc. (HCWB) - 4 SEC Filings 08/23/2021
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 08/13/2021
HCW Biologics Inc. (HCWB) - 10-Q - Quarterly Report SEC Filings 08/13/2021
HCW Biologics Inc. (HCWB) - SC 13D SEC Filings 08/02/2021
HCW Biologics Inc. (HCWB) - 8-K - Current report SEC Filings 07/26/2021
HCW Biologics Inc. (HCWB) - 4 SEC Filings 07/23/2021
HCW Biologics Inc. (HCWB) - S-8 SEC Filings 07/21/2021
HCW Biologics Inc. (HCWB) - 424B4 SEC Filings 07/21/2021
HCW Biologics Inc. (HCWB) - EFFECT SEC Filings 07/20/2021
HCW Biologics Inc. (HCWB) - EFFECT SEC Filings 07/19/2021
HCW Biologics Inc. (HCWB) - S-1MEF SEC Filings 07/19/2021
HCW Biologics Inc. (HCWB) - 3 SEC Filings 07/19/2021
HCW Biologics Inc. (HCWB) - CORRESP SEC Filings 07/16/2021
HCW Biologics Inc. (HCWB) - SEC STAFF LETTER SEC Filings 07/15/2021
HCW Biologics Inc. (HCWB) - CORRESP SEC Filings 07/15/2021
HCW Biologics Inc. (HCWB) - CERT SEC Filings 07/15/2021
HCW Biologics Inc. (HCWB) - CORRESP SEC Filings 07/13/2021
HCW Biologics Inc. (HCWB) - FWP SEC Filings 07/12/2021
HCW Biologics Inc. (HCWB) - S-1/A SEC Filings 07/09/2021
HCW Biologics Inc. (HCWB) - 8-A12B SEC Filings 07/09/2021
HCW Biologics Inc. (HCWB) - S-1/A SEC Filings 07/07/2021
HCW Biologics Inc. (HCWB) - FWP SEC Filings 07/07/2021
HCW Biologics Inc. (HCWB) - SEC STAFF LETTER SEC Filings 06/22/2021
HCW Biologics Inc. (HCWB) - S-1/A SEC Filings 06/15/2021
HCW Biologics Inc. (HCWB) - CORRESP SEC Filings 06/15/2021
HCW Biologics Inc. (HCWB) - UPLOAD SEC Filings 06/10/2021
HCW Biologics Inc. (HCWB) - CORRESP SEC Filings 06/04/2021
HCW Biologics Inc. (HCWB) - S-1 SEC Filings 05/26/2021
HCW Biologics Inc. (HCWB) - CORRESP SEC Filings 05/26/2021
HCW Biologics Inc. (HCWB) - UPLOAD SEC Filings 05/13/2021
HCW Biologics Inc. (HCWB) - DRS SEC Filings 04/16/2021
HCW Biologics Inc. (HCWB) - D SEC Filings 10/19/2020

Press Releases

StockPrice Release
Hcw biologics inc. received nasdaq staff determination letter 12/23/2024
Hcw biologics announces pricing of $6.9 million registered direct offering and concurrent private placement priced above market under nasdaq rules 11/18/2024
Hcw biologics and wy biotech announce license agreement for immunotherapeutic product candidate 11/18/2024
Hcw biologics reports third quarter 2024 financial results and business highlights 11/14/2024
Hcw biologics reports second quarter 2024 financial results and business highlights - correction 08/23/2024
Hcw biologics reports second quarter 2024 financial results and business highlights 08/14/2024
Hcw biologics reports first quarter 2024 financial results and business highlights 05/15/2024
Hcw biologics reports fourth quarter 2023 and fiscal year end financial results and business highlights 04/01/2024
Hcw biologics reports third quarter 2023 financial results and recent business highlights 11/14/2023
Investigator sponsor of hcw biologics' phase 1 clinical trial presented human data readout and anti-cancer mechanism of action of hcw9218 at 38th sitc annual meeting 11/08/2023
Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting 11/01/2023
Hcw biologics participating at h.c. wainwright 25th annual global investment conference in new york on september 11 – 13, 2023 09/06/2023
Hcw biologics reports second quarter 2023 financial results and recent business highlights 08/11/2023
Hcw biologics is granted third fundamental patent: u.s. patent for methods of treating age-related disorders 06/14/2023
Hcw biologics reports first quarter 2023 financial results and recent business highlights 05/09/2023
Hcw biologics secures $26.25 million non-dilutive financing with asset-backed development loan 04/27/2023
Hcw biologics poster presentation at aacr annual meeting 2023 04/13/2023
A novel immunotherapeutic approach to treating aging-associated diseases 04/03/2023
Hcw biologics reports fourth quarter and full year 2022 financial results and recent business highlights 03/28/2023
Hcw biologics enters crada with national cancer institute 12/08/2022
Hcw biologics is granted second fundamental patent: u.s. patent for multi-chain chimeric polypeptide created with tobi™ platform 12/07/2022
Hcw biologics reports third quarter 2022 financial results and recent business highlights 11/07/2022
Hcw biologics reports second quarter 2022 financial results and recent business highlights 08/12/2022
U.s. patent issued to hcw biologics for foundational platform technology 08/03/2022
Hcw biologics to participate in h.c. wainwright annual global life sciences conference may 23 – 25, 2022 05/23/2022
Hcw biologics reports first quarter 2022 financial results and recent business highlights 05/13/2022
Hcw biologics to showcase two novel groups of fusion molecules created with proprietary and versatile tobi™ platform at the 105th annual meeting of the american association of immunologists 05/05/2022
Hcw biologics' ceo hing c. wong, ph.d. 04/19/2022
Hcw biologics reports fourth quarter and full year 2021 financial results and business highlights for 2021 03/28/2022
Hcw biologics to present at 2022 virtual growth conference sponsored by the maxim group and m-vest 03/24/2022
Masonic cancer center at the university of minnesota receives fda clearance to proceed with phase 1 clinical trial in solid tumors for hcw9218, hcw biologics' novel bifunctional fusion protein 01/24/2022
Hcw biologics inc. announces its lead product candidate shown to augment anti-tumor activity and reduce side effects of chemotherapy regimens 01/20/2022
Hcw biologics to participate in h.c. wainwright bioconnect conference january 10 – 13, 2022 01/06/2022
Hcw biologics' founder and ceo dr. hing c. wong named weaver h. 12/13/2021
Hcw biologics receives fda clearance to proceed with phase 1b clinical trial for immunotherapeutic hcw9218 for pancreatic cancer 10/28/2021
Hcw biologics announces appointment of two new members to board of directors 10/27/2021
Hcw biologics showcases scientific paper in molecular therapy highlighting potential of hcw9218 as novel, bifunctional cancer immunotherapeutic 08/24/2021
Hcw biologics' article published in cancer immunology research validates novel tissue factor scaffold fusion protein (tobi™) discovery platform 08/17/2021
Hcw biologics reports second quarter financial results and recent business highlights 08/13/2021
Hcw biologics inc. announces closing of $56.0 million initial public offering 07/22/2021
Hcw biologics inc. announces pricing of $56.0 million initial public offering 07/19/2021

More Headlines

News
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights MIRAMAR, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2024. 05/15/2024
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023. 04/01/2024
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2023. 11/14/2023
Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting Showed HCW9218 clinical safety and tumor response endpoints for 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable disease MIRAMAR, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced results from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, in patients with solid tumors who failed at least two prior lines of therapy. 11/08/2023
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota. 11/01/2023
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023 Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months 09/06/2023
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023. 08/11/2023
HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying US crude oil futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. 08/31/2022
HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-Vest Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” 03/24/2022
Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc's (NASDAQ: HCWB) lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tumors with progressive disease after prior chemotherapies. HCW9218 is an injectable, bifunctional fusion protein complex designed to drive anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities. 01/24/2022
HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo HCW Biologics Inc (NASDAQ: HCWB) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218. The preclinical data demonstrated that HCW9218 enhanced the anti-tumor efficacy of chemotherapy drugs and diminished their harmful side effects by reducing therapy-induced senescence (TIS). 01/20/2022
Good Penny Stocks to Buy Right Now? 3 to Watch in November Are these penny stocks worth buying right now? The post Good Penny Stocks to Buy Right Now? 10/28/2021
Making a Penny Stocks Watchlist? Don't Forget These 3 Small-Caps Three penny stocks that could be worth watching in the second half of October The post Making a Penny Stocks Watchlist? Don't Forget These 3 Small-Caps appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 10/19/2021
HCW Biologics Showcases Scientific Paper in Molecular Therapy Highlighting Potential of HCW9218 as Novel, Bifunctional Cancer Immunotherapeutic Lead Drug Candidate Engineered Using Tissue FactOr-Based FusIon (TOBI™) Platform 08/24/2021
HCW Biologics' Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells 08/17/2021
HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2021. 08/13/2021
HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering MIRAMAR, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced the closing of its previously announced underwritten initial public offering of 7,000,000 shares of common stock at a public offering price of $8.00 per share for gross proceeds of $56.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses. All of the shares of common stock were offered by the Company. The shares began trading on the Nasdaq Global Market on July 20, 2021, under the ticker symbol “HCWB.” In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,050,000 shares at the public offering price less the underwriting discounts and commissions. 07/22/2021

Unlock

HCWB Ratings Summary

HCWB Quant Ranking